Comparing treatment persistence, healthcare resource utilization, and costs in adult patients with major depressive disorder treated with escitalopram or citalopram

American Health and Drug Benefits

Volumn 4, Issue 2, 2011, Pages 78-87

  Wu, Eric Q ^a   Greenberg, Paul E ^a   ben Hamadi, Rym ^a   Yu, Andrew P ^a   Yang, Elaine H ^a   Erder, M Haim ^b  

^a Health Economics   (United States)

^b Forest Research Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; ESCITALOPRAM; GENERIC DRUG;

ADULT; ARTICLE; CLINICAL EFFECTIVENESS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG EFFICACY; DRUG USE; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MEDICAL FEE; OUTCOME ASSESSMENT; PRESCRIPTION; TREATMENT DURATION;

EID: 79955990597     PISSN: 19422962     EISSN: 19422970     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289:3095-3105.
2. Bloom BS. Prevalence and economic effects of depression. Manag Care. 2004;13(6 suppl):9-16.
3. Ostacher MJ. Comorbid alcohol and substance abuse dependence in depression: impact on the outcome of antidepressant treatment. Psychiatr Clin North Am. 2007;30:69-76.
4. Croom KF, Plosker GL. Spotlight on the pharmacoeconomics of escitalopram in depression. CNS Drugs. 2004;18:469-473.
5. Greenberg PE, Kessler RC, Birnbaum HG, et al. The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry. 2003;64:1465-1475.
6. Weilburg JB. An overview of SSRI and SNRI therapies for depression. Manag Care. 2004;13:25-33.
7. Fantino B, Moore N, Verdoux H, Auray JP. Cost-effectiveness of escitalopram vs. citalopram in major depressive disorder. Int Clin Psychopharmacol. 2007;22:107-115.
8. Esposito D, Wahl P, Daniel G, et al. Results of a retrospective claims database analysis of differences in antidepressant treatment persistence associated with escitalopram and other selective serotonin reuptake inhibitors in the United States. Clin Ther. 2009;31:644-656.
9. Wu EQ, Greenberg PE, Yang E, et al. Treatment persistence, healthcare utilisation and costs in adult patients with major depressive disorder: a comparison between escitalopram and other SSRI/SNRIs. J Med Econ. 2009;12:124-135.
10. Burke WJ, Gergel I, Bose A. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry. 2002;63:331-336.
11. Lepola UM, Loft H, Reines EH. Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol. 2003;18:211-217.
12. Rapaport MH, Bose A, Zheng H. Escitalopram continuation treatment prevents relapse of depressive episodes. J Clin Psychiatry. 2004;65:44-49.
13. Wade A, Despiegel N, Heldbo Reines E. Escitalopram in the long-term treatment of major depressive disorder. Ann Clin Psychiatry. 2006;18:83-89.
14. Moore N, Verdoux H, Fantino B. Prospective, multicentre, randomized, doubleblind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. Int Clin Psychopharmacol. 2005;20:131-137.
15. Wu E, Greenberg PE, Yang E, et al. Comparison of escitalopram versus citalopram for the treatment of major depressive disorder in a geriatric population. Curr Med Res Opin. 2008;24:2587-2595.
16. Antidepressant medication management. The state of health care quality 2006. National Committee for Quality Assurance; Washington, DC; 2006. www.ncqa.org/Portals/0/Publications/Resource%20Library/SOHC/SOHC_2006.pdf. Accessed Feb-ruary 28, 2011.
17. McCombs JS, Luo M, Johnstone BM, Shi L. The use of conventional antipsychotic medications for patients with schizophrenia in a Medicaid population: therapeutic and cost outcomes over 2 years. Value Health. 2000;3:222-231.
18. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613-619.
19. Birnbaum HG, Ben-Hamadi R, Greenberg PE, et al. Determinant of direct cost differences among US employees with major depressive disorders using antidepressants. Pharmacoeconomics. 2009;27:507-517.
20. Patient compliance in depression. Based on a presentation by James Jefferson, MD. Am J Manag Care. 2000;6(2 suppl):S31-S38.
21. Revicki DA, Simon GE, Chan K, et al. Depression, health-related quality of life, and medical cost outcomes of receiving recommended levels of antidepressant treatment. J Fam Pract. 1998;47:446-452.
22. Thompson D, Buesching D, Gregor KJ, Oster G. Patterns of antidepressant use and their relation to costs of care. Am J Manag Care. 1996;2:1239-1246.
23. Demyttenaere K, Hemels ME, Hudry J, Annemans L. A cost-effectiveness model of escitalopram, citalopram, and venlafaxine as first-line treatment for major depressive disorder in Belgium. Clin Ther. 2005;27:111-124.
24. Hemels ME, Kasper S, Walter E, Einarson TR. Cost-effectiveness of escitalopram versus citalopram in the treatment of severe depression. Ann Pharmacother. 2004;38: 954-960.
25. Sullivan PW, Valuck R, Saseen J, MacFall HM. A comparison of the direct costs and cost effectiveness of serotonin reuptake inhibitors and associated adverse drug reactions. CNS Drugs. 2004;18:911-932.
26. Wade AG, Toumi I, Hemels ME. A probabilistic cost-effectiveness analysis of escitalopram, generic citalopram and venlafaxine as a first-line treatment of major depressive disorder in the UK. Curr Med Res Opin. 2005;21:631-642.
27. Wade AG, Toumi I, Hemels ME. A pharmacoeconomic evaluation of escitalopram versus citalopram in the treatment of severe depression in the United Kingdom. Clin Ther. 2005;27:486-496.
28. Hess LM, Raebel MA, Conner DA, Malone DC. Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann Pharmacother. 2006;40:1280-1288.
29. Turner BJ, Newschaffer CJ, Zhang D, et al. Antiretroviral use and pharmacybased measurement of adherence in postpartum HIV-infected women. Med Care. 2000;38:911-925.
30. Wilensky J, Fiscella RG, Carlson AM, et al. Measurement of persistence and adherence to regimens of IOP-lowering glaucoma medications using pharmacy claims data. Am J Ophthalmol. 2006;141(1 suppl):S28-S33.